Leading the way to safer medication
 Crosscheck  Recommender


Therapeutic Indications

Binimetinib is indicated for:

Unresectable or metastatic melanoma with a BRAF V600 mutation

Irrespective of gender only Adults (18 years old or older)

Binimetinib in combination with encorafenib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation.

For this indication, the medical literature mentions below treatments (click for details):

Treatment 1: Oral - 90 mg divided into 2 equal doses


Active ingredient Binimetinib is contraindicated in the following cases: